Algert Global LLC increased its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 110.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 131,400 shares of the company's stock after acquiring an additional 69,040 shares during the quarter. Algert Global LLC owned approximately 0.31% of Amphastar Pharmaceuticals worth $2,652,000 at the end of the most recent quarter.
Several other institutional investors also recently made changes to their positions in the stock. Rice Hall James & Associates LLC raised its stake in shares of Amphastar Pharmaceuticals by 54.6% in the first quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company's stock valued at $3,670,000 after purchasing an additional 66,172 shares in the last quarter. Denali Advisors LLC grew its holdings in shares of Amphastar Pharmaceuticals by 56.9% in the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company's stock worth $5,671,000 after purchasing an additional 76,765 shares during the last quarter. Pacer Advisors Inc. raised its position in Amphastar Pharmaceuticals by 47.1% in the 1st quarter. Pacer Advisors Inc. now owns 261,483 shares of the company's stock valued at $5,122,000 after purchasing an additional 83,739 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Amphastar Pharmaceuticals by 12.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company's stock worth $39,726,000 after purchasing an additional 228,262 shares during the last quarter. Finally, Cibc World Market Inc. acquired a new stake in shares of Amphastar Pharmaceuticals in the fourth quarter valued at $1,666,000. 65.09% of the stock is owned by institutional investors.
Insider Buying and Selling
In other news, CFO William J. Peters sold 8,180 shares of the company's stock in a transaction on Friday, August 7th. The stock was sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the sale, the chief financial officer directly owned 172,846 shares in the company, valued at $3,885,578.08. This represents a 4.52% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard K. Prins sold 7,973 shares of the firm's stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $20.30, for a total value of $161,851.90. Following the completion of the transaction, the director directly owned 29,625 shares in the company, valued at approximately $601,387.50. This represents a 21.21% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 29.60% of the stock is currently owned by corporate insiders.
Wall Street Analyst Weigh In
AMPH has been the subject of a number of recent analyst reports. Bank of America reiterated an "underperform" rating and issued a $20.00 price objective (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating for the company in a research note on Friday, August 7th. Zacks Research raised Amphastar Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, July 21st. Needham & Company LLC reissued a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Finally, Weiss Ratings reiterated a "sell (d+)" rating on shares of Amphastar Pharmaceuticals in a report on Wednesday, July 8th. Six investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of "Reduce" and an average price target of $22.50.
Read Our Latest Stock Analysis on Amphastar Pharmaceuticals
Amphastar Pharmaceuticals Stock Performance
Amphastar Pharmaceuticals stock opened at $22.01 on Friday. The company has a market capitalization of $936.31 million, a PE ratio of 13.02, a P/E/G ratio of 4.22 and a beta of 0.89. Amphastar Pharmaceuticals, Inc. has a twelve month low of $16.65 and a twelve month high of $31.26. The company has a quick ratio of 1.71, a current ratio of 2.40 and a debt-to-equity ratio of 0.79. The firm has a fifty day simple moving average of $20.22 and a two-hundred day simple moving average of $20.79.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $0.91 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a net margin of 10.76% and a return on equity of 14.98%. The firm had revenue of $183.90 million for the quarter, compared to analysts' expectations of $179.92 million. Research analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.46 EPS for the current year.
Amphastar Pharmaceuticals Profile
(
Free Report)
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
Featured Stories
Want to see what other hedge funds are holding AMPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Amphastar Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amphastar Pharmaceuticals wasn't on the list.
While Amphastar Pharmaceuticals currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
